There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...

If the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...

Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...

A groundbreaking cooling technology from Saudi Arabia offers a solution to rising energy costs. Researchers at KAUST have created Nescod, a...

Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...

A groundbreaking cooling system called Nescod is here. Developed by scientists, it cools without electricity. This innovation uses common m...

Kuehne+Nagel has boosted its healthcare logistics in India by opening a new temperature-controlled airfreight facility in Hyderabad.

In the current phase of market volatility, the only solace to be derived is from market history. And history tells us that, just like good ...

The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...

Over the next few sessions, as the uncertainty caused by the Gulf war intensifies and makes you anxious, remember this: It is not the first...

India's pharma exports saw a sharp 23.17% fall in March. The West Asia war disrupted shipping routes and air transit hubs. This led to incr...

What is evident in the last few trading sessions is how the street is treating Q4 earnings numbers. If a company delivers in terms of numbe...

Despite the US and Iran failing to reach an agreement over the weekend, the street is not entirely in a bearish mood. Market breadth is not...

Currently pegged at USD 41 billion, Indian pharmaceuticals market is expected to reach USD 65 billion by 2024 and to USD120 billion by 2030...

The world does not have sufficient installed capacity to supply the 11-13 billion doses of Covid vaccines required and their ingredients.

Mumbai-based VAV Lifesciences is the only domestic firm in the COVID-19 vaccine supply chain with this crucial ingredient. It can thus can ...

The government must also work out models and modules for improvised hospitals for Covid care, including oxygen delivery systems simpler tha...